子参数与蒂尔泽帕提德在肥胖与或没有2型糖尿病
Hiddo J L Heerspink1, Allon N Friedman2, Petter Bjornstad3
1Department of Clinical Pharmacy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Journal of the American Society of Nephrology : JASN
|June 13, 2025
概括
在超重或肥胖,有或没有2型糖尿病的个体中,蒂尔泽帕提德显著降低了白色素尿. 通过估计的膜过率 (eGFR) 测量功能,在提尔泽帕提德治疗时没有出现不良变化.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
- 代谢疾病 代谢疾病
背景情况:
- 蒂尔泽帕提德是一种双重依赖葡萄糖的胰岛素型多和类似葡萄糖-1受体激动剂,在患有高心血管风险的2型糖尿病患者中表现出脏保护作用.
- 这项研究研究了提尔泽帕提德对超重/肥胖,有或没有2型糖尿病的个体的功能的影响.
研究的目的:
- 评估蒂尔泽帕提德使用与功能参数之间的关联,特别是尿中的白蛋白与肌素的比率 (UACR) 和估计的淋巴球过率 (eGFR).
- 为了在两个不同的群体中评估这些影响:没有2型糖尿病的超重/肥胖患者 (SURMOUNT-1) 和2型糖尿病患者 (SURMOUNT-2).
主要方法:
- 对SURMOUNT-1和SURMOUNT-2随机对照试验的后期分析.
- 参与者接受了提尔泽帕提德 (5,10或15毫克) 或安慰剂,在每个试验中,提尔泽帕提德组被组合在一起.
- 关键评估包括从基线到第72周的UACR和eGFR (使用肌素,囊素-C和组合方程) 的变化.
主要成果:
- 在这两项试验中,tirzepatide的使用与安慰剂相比,在72周的UACR显著降低 (-8.4%在SURMOUNT-1,-31.1%在SURMOUNT-2).
- 在基线较高的UACR (≥30 mg/g) 的参与者中,UACR的减少更为明显.
- 蒂尔泽帕提德与SURMOUNT-1中增加的eGFR (基于cystatin-C) 有关,但在SURMOUNT-2中没有观察到eGFR变化的显著差异.
结论:
- 蒂尔泽帕提德在超重/肥胖个体中对白蛋白尿有有益影响,无论2型糖尿病的状况如何.
- 治疗没有对估计的膜过率产生不良影响.
- 这些发现支持蒂尔泽帕提德在管理患者群体中脏健康方面的潜在作用.
相关概念视频
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
90
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
90
01:21Drug Dosing: Obese Patients
108
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
108
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
129
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
129
01:28Chronic Kidney Disease III: Interprofessional Care
231
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
231
01:16Insulin: Dosing Regimen and Adverse Effects
510
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
510
01:23Dipeptidyl Peptidase 4 Inhibitors
418
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
418